An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

计划入组 21 人 · 首次发布于 2021 年 10 月 20 日

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

计划入组 22 人 · 首次发布于 2012 年 2 月 10 日

Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

计划入组 81 人 · 首次发布于 2026 年 9 月 1 日

Usher Syndrome Type 3 (Prime Medicine)

RNA editing therapy (Usher syndrome type II)

Usher Syndrome (Saliogen Therapeutics)

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

RETT SYNDROME RESEARCH TRUST

United States

Entrada Therapeutics Advances RNA-Based Pipeline with First Ocular Candidate for Usher Syndrome

AAVantgarde Bio Doses First Patient in Phase 1/2 Trial of AAVB-081 for Usher Syndrome Type 1B

Lyora Therapeutics Launches With $2.5M Seed Funding to Advance Genetic Medicines for Inherited Retinal Diseases